Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised RMB 200 million (approximately USD 27.8 million) in a Series A+ financing round. The round was led by Youshan Capital, with participation from SIP Oriza Seed Fund, PagodaTree Partners, and Triwise.
The company’s pipeline features SNC109, a dual CAR-T cell therapy equipped with BiTE armor, which has received orphan drug designation (ODD) status in the U.S. for the treatment of malignant gliomas and tacit clinical trial approval in China. Additionally, Simnova is advancing SNC103, a CAR-NK product currently in Phase I clinical trials. The company has also formed a partnership with U.S. biotech ORNA to develop next-generation universal in vivo cell therapy products utilizing circular mRNA and targeted delivery platforms.- Flcube.com
